Obesity Care Continuum (OCC) Commends Food and Drug Administration (FDA) for their Continued Proactive Support and Approval of New Obesity Treatments
in 2012 News Releases, News Releases on July 18, 2012

Please Note: As of February 2020, the Food and Drug Administration has issued a voluntary withdrawal of Belviq, Belviq XR (lorcaserin) from the U.S. market, as a safety clinical trial has shown an increased occurrence of cancer. Patients currently taking Belviq have been advised to stop taking the medication and speak with their healthcare provider
Read Article